Unresectable gastric cancer with gastric outlet obstruction and distant metastasis responding to intraperitoneal and folfox chemotherapy after palliative laparoscopic gastrojejunostomy: report of a case

[1]  E. Kuipers,et al.  Surgical gastrojejunostomy or endoscopic stent placement for the palliation of malignant gastric outlet obstruction (SUSTENT study): a multicenter randomized trial. , 2010, Gastrointestinal endoscopy.

[2]  S. Ikeda,et al.  Safety and efficacy of bidirectional chemotherapy for treatment of patients with peritoneal dissemination from gastric cancer: Selection for cytoreductive surgery , 2009, Journal of surgical oncology.

[3]  Y. Mok,et al.  Clinical significance of gastric outlet obstruction on the oncologic and surgical outcomes of radical surgery for carcinoma of the distal stomach , 2009, Journal of surgical oncology.

[4]  Jian-guo Shen,et al.  Neoadjuvant chemotherapy versus surgery alone for locally advanced gastric cancer: a retrospective comparative study. , 2008, Hepato-Gastroenterology.

[5]  Zhi-fang Liu,et al.  Biweekly Oxaliplatin in Combination With Continuous Infusional 5-Fluorouracil and Leucovorin (Modified FOLFOX-4 Regimen) as First-Line Chemotherapy for Elderly Patients With Advanced Gastric Cancer , 2008, American journal of clinical oncology.

[6]  Masahiro Takeuchi,et al.  S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. , 2008, The Lancet. Oncology.

[7]  F. Uchikoshi,et al.  Unresectable gastric cancer with multiple liver metastases effectively treated with combined paclitaxel and doxifluridine chemotherapy , 2006, International Journal of Clinical Oncology.

[8]  S. Boccia,et al.  Response to neoadjuvant chemotherapy and effects of tumor regression in gastric cancer. , 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[9]  J. Ajani,et al.  Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Takuma Sasaki,et al.  Neoadjuvant treatment of gastric cancer with peritoneal dissemination. , 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[11]  L. Cavanna,et al.  Oxaliplatin in Combination With 5-Fluorouracil (5-FU) and Leucovorin (LV) in Patients With Metastatic Gastric Cancer (MGC) , 2006, American journal of clinical oncology.

[12]  F. Lordick,et al.  Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer , 2005, British Journal of Cancer.

[13]  P. Sugarbaker,et al.  Clinical Pathway for the Management of Resectable Gastric Cancer with Peritoneal Seeding: Best Palliation with a Ray of Hope for Cure , 2000, Oncology.

[14]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.

[15]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[16]  PhD Hiroshi Okabe MD,et al.  Induction Chemotherapy with S-1 Plus Cisplatin Followed by Surgery for Treatment of Gastric Cancer with Peritoneal Dissemination , 2009, Annals of Surgical Oncology.

[17]  K. Higuchi,et al.  Histological complete response in advanced gastric cancer after 2 weeks of S-1 administration as neoadjuvant chemotherapy , 2005, Gastric Cancer.